Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus

Journal of the American Geriatrics Society

Volumn 58, Issue 4, 2010, Pages 799-801

  Sleegers, Monique J M ^a   Beutler, Jaap J ^a   Hardon, Willem J ^a   Berden, Jo H M ^b   Verhave, Jacobien C ^b   Conemans, Jean M H ^a   Hollander, Daan A M J ^a   Dautzenberg, Paul L J ^a   Hoogeveen, Ellen K ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALPROIC ACID;

AGED; ANAMNESIS; APRAXIA; CASE REPORT; COGNITIVE DEFECT; DEMENTIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GENERALIZED EPILEPSY; HUMAN; KIDNEY FAILURE; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; PARKINSONISM; RAPIDLY PROGRESSIVE DEMENTIA; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGED; ANTICONVULSANTS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EPILEPSY, GENERALIZED; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENTAL STATUS SCHEDULE; PARKINSON DISEASE, SECONDARY; VALPROIC ACID;

EID: 77950451567     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02795.x     Document Type: Letter

References (9)

1. Geschwind MD, Shu H, Haman A et al. Rapidly progressive dementia. Ann Neurol 2008 64:97 108.
2. The American College Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 42:599 608.
3. Trevisani VF, Castro AA, Neves Neto JF et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006; 19; CD005117.
4. Armon C, Shin C, Miller P et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 2006 47:626 635.
5. Masmoudi K, Gras-Champel V, Masson H et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: A report of ten cases. Pharmacopsychiatry 2006 39:9 12.
6. Ristić AJ, Vojvodić N, Janković S et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment; a study of 364 patients with different types of epilepsy. Epilepsia 2006 47:2183 2185.
7. Zaret BS, Cohen RA. Reversible valproic acid-induced dementia: A case report. Epilepsia 1986 27:234 240.
8. Papazian O, Cañizales E, Alfonso I et al. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol 1995 38:687 691.
9. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clinica Chemica Acta 2007 377:1 13.